Dario Amodei says Anthropic will cure diseases, resist pressure in record IPO

Direct Source Verification: This story is aggregated from India Today (indiatoday.in). Full reporting rights and copyright belong to the primary publisher.
Anthropic officially entered the public stock market on Thursday, November 19, ringing the opening bell at the Nasdaq in what is now the biggest initial public offering (IPO) in history. Yet, even on the biggest financial day of the company’s five-year journey, CEO Dario Amodei m...

Anthropic officially entered the public stock market on Thursday, November 19, ringing the opening bell at the Nasdaq in what is now the biggest initial public offering (IPO) in history. Yet, even on the biggest financial day of the company’s five-year journey, CEO Dario Amodei made one thing clear: Anthropic will not rush artificial intelligence at the cost of safety.

Standing at the Nasdaq alongside his sister and co-founder Daniela Amodei, Dario read his speech from a printout and later shared the full remarks on X. He said that becoming a public company gives Anthropic stronger financial backing, which will only help it stay focused on building AI responsibly.

"To state it unequivocally, we will pace the training and deployment of AI systems, taking as long as is necessary to have confidence that they are safe and will remain under human control," Amodei said. "We will not bend to either business or political pressure."Why Dario and Daniela started Anthropic

Amodei began his speech on a personal note. He shared that he and Daniela lost their father to a disease that became curable just a few years later. That loss pushed him into biology, hoping to help medical treatments arrive sooner.

While human intelligence has largely defeated diseases like smallpox, polio, and the plague, Amodei noted that progress on other illnesses is still too slow because there are too few scientists and too little time. He said scientists are finding Anthropic’s Claude chatbot to speed up work in protein folding, drug design, cancer genetics, and clinical trials.

"I believe sufficiently powerful AI, working in concert with humans, could compress a century of scientific and medical progress into a decade," he said. However, he warned against getting too carried away, noting that lab work and clinical trials still take time.

Beyond medicine, he pointed out that businesses, nonprofits, and everyday users are already using Claude to boost economic growth and improve public services.'Very real' risks and a 'race to the top'

Amodei was equally honest about the dangers of advanced AI. He highlighted three major risks: misuse by individuals or nation-states, economic disruption, and losing control of AI systems. Still, he stressed that these outcomes are avoidable if AI makers take safety seriously.

Anthropic has built safeguards for biological and cyber threats, along with tools that let researchers look inside AI models like an X-ray. Even so, Amodei admitted that "the most difficult safety work lies ahead of us" and said the company’s top talent must spend even more time double- and triple-checking its systems.

His remarks follow a September plan in which he urged rivals to coordinate on AI safety. OpenAI’s Sam Altman, Google DeepMind’s Demis Hassabis, and xAI’s Elon Musk agreed in principle, though concrete commitments remain limited.

Speaking to CNBC on Thursday, Daniela Amodei echoed her brother’s message, saying the promise of AI is "incredible," but managing its risks remains Anthropic’s core job. Dario also called for a "race to the top," hoping Anthropic’s success proves that companies can prioritise safety and still win big.Record-breaking IPO and share price debut

Now for the numbers that made Wall Street history. Anthropic listed on the Nasdaq under the ticker symbol ANT. Ahead of the debut, it priced its IPO at $83 per share, higher than its earlier $70 to $78 range selling 980 million shares to raise $81.3 billion. That beat Elon Musk’s SpaceX, which held the previous record after its June 2026 listing.

As the first major frontier AI lab to go public, Anthropic is now a key test for the entire AI industry, including rival OpenAI. The company reported $33.24 billion in revenue for the first nine months of 2026 and an annualised revenue run rate of $81 billion by October, though it remains unprofitable as it commits nearly $900 billion to $1 trillion toward future chips and computing infrastructure.- EndsAlso Read | Anthropic employees could become millionaires after IPO: Who stands to gain the most?Also Read | Anthropic researcher warns superhuman AI is 1.3 years away, humans will become permanently unemployableAlso Read | Anthropic hits $2 trillion valuation in blockbuster Nasdaq debut, surpasses SpaceX

I am a journalist covering the ever-evolving consumer tech landscape. From smartphones to laptops, I track the latest drops and decode the data to see if the newest gadgets are worth the hype.

Original Source
https://www.indiatoday.in/technology/news/story/dario-amodei-says-anthropic-will-cure-all-diseases-resist-political-pressure-in-record-breaking-ipo-3042862-2026-11-20?utm_source=rss
Visit India Today ↗
SHARE STORY:
𝕏 f in

Related Coverage in Health